Dallas, Texas, March 30, 2022 (GLOBE NEWSWIRE) -- North American Cannabis Holdings, Inc. (OTC Pink: USMJ) is a cannabis ecommerce business – see www.USMJ.com. “The company’s ecommerce experience could be priceless, in the event marijuana is legalized federally,” said USMJ CEO Steven Rash.
The House is expected to vote this week on marijuana legalization.
“We now have years of experience in the ecommerce business and federal legalization opens the door to massive expansion opportunities that can be built on our ecommerce experience,” said USMJ CEO Steven Rash. “We have the technology and the operations experience in the cannabis space that puts us ahead of the crowd. Think about home delivery to consultation, all from an online portal. Given USMJ’s relationship with Priority Aviation, Inc. (OTC Pink: PJET], don’t forget, let alone underestimate, the resources we have there to tap into PJET’s smart technology. The company’s ecommerce experience could be priceless, in the event marijuana is legalized federally.”
Puration, Inc. (OTC Pink: PURA), PJET and USMJ are all controlled by the same majority shareholder, ACI Conglomerated. Steven Rash is the senior manager of ACI in addition to serving as the interim CEO of PJET following PJET’s business focus realignment into the student life market.
Yesterday, USMJ published a shareholder update highlighting the company’s recent opportunity to become a licensed marijuana cultivator and distributor:
USMJ Details $20 Million Marijuana and CBD Sales Growth Plan In Shareholder Update
Visit the company’s ecommerce site now and bookmark the site to watch for more coming announcements and updates: www.USMJ.com
Contact:
USMJ
Steven Rash
info@aciconglomerated.com
+1 (800) 861-1350
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
